Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

Morschhauser, Franck ; Flinn, Ian W ; Advani, Ranjana ; Sehn, Laurie H ; Diefenbach, Catherine ; Kolibaba, Kathryn ; Press, Oliver W ; Salles, Gilles ; Tilly, Hervé ; Chen, Andy I ; Assouline, Sarit ; Cheson, Bruce D ; Dreyling, Martin ; Hagenbeek, Anton ; Zinzani, Pier Luigi ; Jones, Surai ; Cheng, Ji ; Lu, Dan ; Penuel, Elicia ; Hirata, Jamie ; Wenger, Michael ; Chu, Yu-Waye ; Sharman, Jeff

The Lancet. Haematology, 2019-05, Vol.6 (5), p.e254-e265 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível